Royalty Table

Below are the disclosed royalties Ligand currently receives or is eligible to receive based on future drug approvals. 

Disclosed Licensed Royalties

Licensee Program Annual Royalty Structure on all Sales
Amgen (1) Kyprolis 1.5% – Sales up to and including $250M
2.0% – Sales from $250M - $500M
2.5% – Sales in the range of $500M - $750M
3.0% – Sales greater than $750M
Acrotech/CASI (1) Evomela 20%
SAGE (1) Zulresso 3%
Pfizer (1) Viviant/Conbriza and Duavee 0.5% – Less than $400M
1.5% – Sales from $400M - $1.0B
2.5% – Sales greater than $1.0B
Palvella PTX-022 5.0% - 9.8%
Travere Therapeutics Sparsentan 9%
Viking TR Beta (VK2809 and VK0214) 3.5% - 7.5%
Sermonix Lasofoxifene 6.0% - 10.0%
CStone CS1001 Low single digit royalty
Gloria Various Low single digit royalty
Aldeyra Therapeutics Reproxalap Low single digit royalty
Arcus AB122 Low single digit royalty
Corvus Ciforadenant Single digit royalty
Dianomi Mineral Coated Microparticle 2.0% - 3.0%
Genagon OmniAb-Genagon 4.0% - 6.0%
Genekey PCSK-9 Low single digit royalty
GigaGen OmniAb-GigaGen Mid-single digit royalty
Kira OmniAb-Kira Low to mid-single digit royalty
KSQ Therapeutics OmniAb-KSQ Therapeutics Single digit royalty
MEI Pharma ME-143 and ME-344 Low single digit royalty
Melinta Baxdela 2.5%
iMetabolic OmniAb-iMetabolic <6%
Metavant RVT-1502 Low double digit to mid-teen royalty
Novan SB206 7.0% - 10.0%
Nucorion Various 4.0% - 9.0%
Sedor CE-Budesonide and CE-Meloxicam 8.0% – Less than $25M
10.0% – Sales greater than $25M
Sedor CE-Fosphenytoin 11%
Seelos Various 4.0% - 10.0%
Takeda OmniAb-Takeda Low single digit royalty
Tekada pevonedistat Low single digit royalty
TG Therapeutics IRAK4 6.0% - 9.5%
Verona Ensifentrine (RPL554) Low to mid-single digit royalty
Viking DGAT-1 3.0% - 7.0%
Viking FBPase Inhibitor (VK0612) 7.5% - 9.5%
Viking Oral EPO 4.5% - 8.5%
Viking SARM (VK5211) 7.25% - 9.25%
Xi'an Xintong MB07133 6%
Xi'an Xintong Pradefovir 9%
Zhilkang Hongyi 4-1BB Low single digit royalty
  1. Currently receiving royalty payments